On Friday, Lennar Corporation (NYSE:LEN)’s shares inclined 0.57% to $47.47.
Lennar Corporation (LEN) declared that the Company will release earnings for the second quarter ended May 31, 2015 before the market opens on June 24, 2015. Additionally, the Company will hold a conference call on June 24, 2015 at 11:00 a.m. Eastern Time.
Lennar Corporation, together with its auxiliaries, engages in the homebuilding activities in the United States. The company operates through Homebuilding East, Homebuilding Central, Homebuilding West, Homebuilding Southeast Florida, Homebuilding Houston, Financial Services, Rialto, and Lennar Multifamily segments. Its homebuilding activities primarily comprise the construction and sale of single-family attached and detached homes to first-time, move-up, and active adult homebuyers, in addition to the purchase, development, and sale of residential land.
Lockheed Martin Corporation (NYSE:LMT)’s shares dropped -0.22% to $191.06.
The U.S. Air Force’s newest infrared surveillance and missile warning satellites will be based on Lockheed Martin’s (LMT) modernized A2100 spacecraft, an update that improves system affordability and resiliency while also adding the flexibility to use future payloads. The fifth and sixth Space Based Infrared System (SBIRS) Geosynchronous Earth Orbit (GEO) satellites will receive this advanced spacecraft technology at no additional cost to the existing fixed-price contract.
The SBIRS program is responsible for America’s early missile warning and infrared surveillance missions, which are crucial to global security.
In response to the Department of Defense’s need for more affordable and resilient systems, the Air Force and Lockheed Martin worked to add the A2100 bus update to the 2014 SBIRS block-buy contract, which already saved the Air Force more than $1 billion. The modernized A2100 adds further affordability by using common components, streamlined manufacturing and has a flexible design that reduces the cost to incorporate future, modernized sensor suites.
Lockheed Martin Corporation, a security and aerospace company, engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It also provides administration, engineering, technical, scientific, logistics, and information services. Its Aeronautics segment offers combat and air mobility aircraft, unmanned air vehicles, and related technologies.
At the end of Friday’s trade, MasTec, Inc. (NYSE:MTZ)‘s shares surged 2.01% to $19.29.
MasTec, Inc. (MTZ) declared that its senior administration will be in New York presenting at the Stifel 2015 Industrials Investor Conference on Tuesday, June 16th, at about 1:50 p.m. Eastern time. One-on-one meetings with institutional investors and MasTec’s senior administration are also being arranged as a part of the conference.
MasTec, Inc., an infrastructure construction company, provides engineering, building, installation, maintenance, and upgrade services for energy, utility, and communications infrastructure primarily in the United States. It operates in five segments: Communications, Oil and Gas, Electrical Transmission, Power Generation and Industrial, and Other.
Depomed Inc (NASDAQ:DEPO), ended its Friday’s trading session with -3.40% loss, and closed at $20.74.
Depomed Inc (DEPO) declared it has reached a settlement agreement in its ongoing patent litigation related to an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Depomed’s Zipsor® (diclofenac liquid filled capsules) 25mg tablets. The settlement permits defendant Watson Laboratories Inc. to start selling generic Zipsor on March 24, 2022, or earlier under certain circumstances. The settlement concludes all ongoing ANDA litigation related to Zipsor.
The settlement agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the U.S. District Court for the District of New Jersey.
Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the administration of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
